Tirzepatide vs. Ozempic: What's the difference?
Tirzepatide targets two hormones, Ozempic just one
+1 more

Tirzepatide and Ozempic are both used to manage Type 2 diabetes and support weight loss, but one might be more effective depending on how your body responds. Tirzepatide (sold as Mounjaro and Zepbound) also targets an additional hormone, which can lead to better blood sugar control and more weight loss for some people. Ozempic is a brand-name version of semaglutide, another GLP-1 drug that helps lower blood sugar and curb appetite. Both differ in how they work, their side effects and how much they cost.
Tirzepatide often leads to more weight loss than Ozempic, thanks to its dual hormone action.
Jump to insightSide effects like nausea are common with both drugs but usually improve with time or dose changes.
Jump to insightTirzepatide may be more effective at lowering A1c than Ozempic, especially for people with Type 2 diabetes.
Jump to insightBoth medications are expensive without insurance, but new discount programs can lower costs for some.
Jump to insightHow do tirzepatide and Ozempic work?
Both tirzepatide and Ozempic are GLP-1 medications, which means they help boost the level of the GLP-1 hormone in the body. These hormones help regulate appetite, as well as levels of insulin and blood sugar. While these two drugs are extremely similar in nature, there are a few minor differences in how they function.
Both medications lower A1c levels by increasing insulin secretion in a glucose-dependent manner and slowing glucose absorption, Marlee Bruno, a board-certified physician assistant and founder of Mind Body & Soul Medical in Pensacola, Florida, told us.
But, she went on to say: “Tirzepatide has shown superior glycemic control compared to Ozempic in head-to-head trials. In the SURPASS-2 trial, Tirzepatide lowered A1c by up to 2.4%, compared to 1.9% with semaglutide.”
Tirzepatide
Tirzepatide is the first drug of its type that mimics two naturally occurring hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). GLP-1 slows gastric emptying, enhances satiety and increases insulin release, said Bruno. GIP works to boost insulin sensitivity and further reduce appetite.
This dual-action mechanism works to enhance both satiety and metabolic regulation. Early clinical trials show promising results for both diabetes and weight management, Bruno said.
In the SURMOUNT-1 clinical trial, participants without diabetes lost up to 22.5% of their body weight over 72 weeks using tirzepatide, which was a groundbreaking result in obesity treatment and management. This makes the drug an excellent Ozempic alternative.
Ozempic
Originally approved for Type 2 diabetes management, Ozempic is the popular brand-name version of the GLP-1 drug semaglutide. It helps regulate blood sugar (which is great for those with Type 2 diabetes) while also slowing gastric emptying and increasing feelings of fullness, leading to reduced calorie intake.
Wegovy is another semaglutide drug that has recently been approved by the FDA for chronic weight management. In the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials, semaglutide led to an average weight loss of 14.9% in adults with obesity when paired with lifestyle changes.
» COMPARE: Zepbound vs. Wegovy: Which is best for weight loss?
What are the side effects of tirzepatide and Ozempic?
If there’s one thing all GLP-1 drugs have in common, it’s unpleasant side effects. Most patients taking these drugs report persistent gastrointestinal side effects.
Side effects of weight loss drugs
| Tirzepatide | Nausea, diarrhea, constipation, decreased appetite and vomiting |
|---|---|
| Ozempic | Nausea, vomiting, diarrhea, abdominal pain and constipation |
For the majority of people taking GLP-1 medications, side effects will lessen over time. “Things like adjusting dosage, trying a different brand and supplementing with vitamin B12 can all help make the experience more pleasant,” Bruno told us.
Vitamin B12 taken alongside the GLP-1 drug can help support energy levels and reduce symptoms like fatigue and nausea, said Bruno. “It's a simple yet effective step that can make a big difference in treatment experience and tolerance!”
For most patients, side effects are mild to moderate and typically improve over time or with dose adjustments. Nausea is the most frequently reported symptom with both medications, but it's often manageable, especially when patients start with a lower dose and gradually increase.
How much do tirzepatide and Ozempic cost?
All GLP-1 medications are expensive without insurance. That’s a big drawback, since oftentimes, they aren’t covered — and that’s especially the case when used for weight loss rather than diabetes (which often is approved and covered).
But in November 2023, tirzepatide received FDA approval to be used for weight loss when combined with at least one weight-related medical issue. Ozempic, on the other hand, is not currently approved by the FDA for weight loss. So if you’re planning on using it for that purpose, you’ll likely have to pay for it out of pocket.
Without insurance, you can expect to pay between $1,000 and $1,200 per month for tirzepatide in the form of Zepbound or Mounjaro. In February of 2025, Zepbound’s manufacturer introduced a Self Pay Journey Program that allows those without commercial insurance to purchase single-dose vials at reduced prices.
Zepbound Self Pay Journey Program pricing
| Dose | Price |
|---|---|
| 2.5 mg | $349 per month |
| 5 mg | $499 per month |
| 7.5 mg and 10 mg |
$499 per month (first fill and refills within 45 days) $599 (7.5 mg) or $699 (10 mg) if refilled after 45 days |
How much does Ozempic cost? This drug clocks in at a slightly lower price point of $1,000 to $1,200.
Manufacturers offer online savings programs for Mounjaro, Zepbound and Ozempic, which can drastically lower the price, but these can’t be combined with insurance.
FAQ
Is tirzepatide more effective than Ozempic for diabetes management?
Early studies show that tirzepatide is somewhat more effective than Ozempic for both weight management and the control of diabetes. This could be thanks to its dual-receptor agonists, consisting of both GIP and GLP-1, rather than just GLP-1, like Ozempic.
Are there any serious side effects associated with tirzepatide or Ozempic?
Yes. There is a small chance of very serious side effects like thyroid tumors, pancreatitis, hypoglycemia and kidney failure.
While these are serious side effects, the vast majority of people who take tirzepatide only suffer minor side effects like nausea, vomiting and diarrhea, which are the same common side effects faced by Ozempic users.
What makes tirzepatide different from Ozempic?
The major difference between tirzepatide and Ozempic is that tirzepatide is a dual agonist drug with both GIP and GLP-1 hormones, while Ozempic is only a GLP-1 receptor agonist.
Why might a doctor prescribe tirzepatide over Ozempic?
It often comes down to the individual patient’s goals, tolerance and coverage — or sometimes, the price. For patients with Type 2 diabetes and obesity, tirzepatide may be preferred due to its superior A1c and weight loss results. However, if a patient is already on a GLP-1 and tolerating it well, or if insurance doesn’t cover tirzepatide, Ozempic may be the best option.
Which medication is more effective for weight loss?
In head-to-head studies, tirzepatide consistently outperforms semaglutide. Patients on higher doses of tirzepatide lost up to 22.5% of body weight, while those on semaglutide (Ozempic) lost around 14.9%. The additional GIP action gives tirzepatide the edge in terms of metabolic impact, Bruno said. This makes tirzepatide the stronger choice for patients whose primary goal is significant weight loss.
» MORE: 6 weight loss medication options
Article sources
ConsumerAffairs writers primarily rely on government data, industry experts and original research from other reputable publications to inform their work. Specific sources for this article include:
- New England Journal of Medicine, "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." Accessed April 8, 2025.
- New England Journal of Medicine, "Tirzepatide Once Weekly for the Treatment of Obesity." Accessed April 8, 2025.
- New England Journal of Medicine, "Once-Weekly Semaglutide in Adults with Overweight or Obesity." Accessed April 7, 2025.
- JAMA Network, "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity." Accessed April 8, 2025.